OncoSec Medical - ONCS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.00
  • Forecasted Upside: 986.72 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.46
▼ -0.0276 (-5.66%)

This chart shows the closing price for ONCS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New OncoSec Medical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ONCS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ONCS

Analyst Price Target is $5.00
▲ +986.72% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for OncoSec Medical in the last 3 months. The average price target is $5.00, with a high forecast of $5.00 and a low forecast of $5.00. The average price target represents a 986.72% upside from the last price of $0.46.

This chart shows the closing price for ONCS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in OncoSec Medical. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/14/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/13/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/11/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/9/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/9/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/8/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/6/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/6/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/16/2022BTIG ResearchLower TargetBuy$10.00 ➝ $5.00Medium
10/17/2021BTIG ResearchInitiated CoverageBuy$10.00High
6/15/2021BTIG ResearchReiterated RatingBuy$10.00High
4/15/2021Alliance Global PartnersBoost TargetPositive ➝ Buy$6.50 ➝ $11.00High
3/25/2021Maxim GroupBoost TargetPositive ➝ Buy$8.00 ➝ $12.00Medium
3/8/2021BTIG ResearchInitiated CoverageBuy$10.00Medium
8/27/2020Dawson JamesReiterated RatingBuyMedium
8/18/2020Maxim GroupReiterated RatingBuy$5.00Low
8/9/2020LADENBURG THALM/SH SHInitiated CoverageMarket Perform ➝ Buy$8.00High
7/27/2020Dawson JamesInitiated CoverageBuy$10.00Low
7/14/2020Alliance Global PartnersLower TargetPositive ➝ Buy$9.00 ➝ $6.50High
10/10/2019Maxim GroupSet TargetBuy$6.00Low
7/31/2019Maxim GroupSet TargetBuy$6.00N/A
6/28/2019Maxim GroupReiterated RatingBuy$10.00Medium
4/1/2019Maxim GroupReiterated RatingBuy$50.00High
12/12/2018Maxim GroupSet TargetBuy$50.00Low
11/29/2018Maxim GroupSet TargetBuy$50.00Low
11/16/2018Maxim GroupSet TargetBuy$50.00Low
11/7/2018Dawson JamesDowngradeBuy ➝ NeutralLow
11/7/2018HC WainwrightDowngradeBuy ➝ NeutralHigh
11/6/2018Piper Jaffray CompaniesLower TargetOverweight$50.00 ➝ $30.00High
10/22/2018HC WainwrightSet TargetBuy$40.00High
10/16/2018HC WainwrightInitiated CoverageBuy$40.00High
10/15/2018Piper Jaffray CompaniesReiterated RatingOverweightLow
8/14/2018Piper Jaffray CompaniesBoost TargetOverweight$50.00Medium
8/7/2018HC WainwrightSet TargetBuy$40.00High
7/31/2018HC WainwrightSet TargetBuy$40.00Low
7/17/2018HC WainwrightSet TargetBuy$40.00High
7/16/2018Dawson JamesReiterated RatingBuyLow
6/29/2018HC WainwrightSet TargetBuy$40.00High
5/9/2018HC WainwrightSet TargetBuy$40.00Medium
5/8/2018Maxim GroupSet TargetBuy$50.00Low
4/23/2018HC WainwrightLower TargetBuy ➝ Buy$60.00 ➝ $40.00Medium
4/16/2018Maxim GroupSet TargetBuy$50.00Low
3/15/2018Maxim GroupSet TargetBuy$50.00High
2/9/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$40.00Low
1/19/2018HC WainwrightSet TargetBuy$60.00Medium
12/15/2017HC WainwrightSet TargetBuy$60.00High
12/14/2017Maxim GroupSet TargetBuy$50.00Low
11/9/2017HC WainwrightReiterated RatingBuy$60.00N/A
10/26/2017Maxim GroupReiterated RatingBuy$50.00N/A
10/10/2017Maxim GroupReiterated RatingBuy$50.00N/A
(Data available from 10/6/2017 forward)

News Sentiment Rating

0.01 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
4/9/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/9/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/8/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/8/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/7/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/6/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/6/2022

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Very Positive

  • No very positive mentions tracked during this time.
OncoSec Medical logo
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor. It is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in clinical trials collaboration and supply agreement (KEYNOTE-695) and metastatic triple negative breast cancer, which is in Phase II clinical trials (KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, the company is developing monotherapy biomarker study in patients with advanced or metastatic TNBC that has completed the Phase II clinical trials; and technology to treat liver, lung, bladder, pancreatic, and other visceral lesions. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890 studies; a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine; a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park's intravital microscopy and enhanced IL-12 DNA-plasmid; and collaboration with Providence Cancer Institute. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. The company was incorporated in 2008 and is headquartered in Pennington, New Jersey.
Read More

Today's Range

Now: $0.46
Low: $0.46
High: $0.46

50 Day Range

MA: $0.64
Low: $0.49
High: $0.74

52 Week Range

Now: $0.46
Low: $0.41
High: $2.08

Volume

1 shs

Average Volume

22,314 shs

Market Capitalization

$18.11 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.91

Frequently Asked Questions

What sell-side analysts currently cover shares of OncoSec Medical?

The following Wall Street analysts have issued research reports on OncoSec Medical in the last twelve months: BTIG Research, and StockNews.com.
View the latest analyst ratings for ONCS.

What is the current price target for OncoSec Medical?

1 Wall Street analysts have set twelve-month price targets for OncoSec Medical in the last year. Their average twelve-month price target is $5.00, suggesting a possible upside of 925.2%. BTIG Research has the highest price target set, predicting ONCS will reach $5.00 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $5.00 for OncoSec Medical in the next year.
View the latest price targets for ONCS.

What is the current consensus analyst rating for OncoSec Medical?

OncoSec Medical currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ONCS will outperform the market and that investors should add to their positions of OncoSec Medical.
View the latest ratings for ONCS.

What other companies compete with OncoSec Medical?

How do I contact OncoSec Medical's investor relations team?

OncoSec Medical's physical mailing address is 3565 GENERAL ATOMICS COURT, SAN DIEGO CA, 92121. The biotechnology company's listed phone number is (858) 662-6732 and its investor relations email address is [email protected] The official website for OncoSec Medical is www.oncosec.com. Learn More about contacing OncoSec Medical investor relations.